Ligand Pharmaceuticals Inc (NASDAQ:LGND) Stock Price While Sentiment Improves

05/05/2015 – Ligand Pharmaceuticals Incorporated was downgraded to “sell” by analysts at Zacks. Following the completion of the transaction, the insider now directly owns 98,341 shares in the company, valued at $11,033,860.20. Comcast Corp now has $189.24 billion valuation. Aperio Gru Limited Liability Company reported 0% of its portfolio in Ebix Inc (NASDAQ:EBIX). Tyers Asset Management LLC now owns 1,036 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 196 shares during the last quarter. (NASDAQ:LGND) shares with value of $630,650 were sold by FOEHR MATTHEW W. Aryeh Jason also sold $4.13M worth of Ligand Pharmaceuticals Inc.

Ratings analysis reveals 80% of Ligand Pharmaceuticals’s analysts are positive. The firm has “Overweight” rating given on Wednesday, April 13 by Stephens. As per Monday, July 17, the company rating was maintained by Deutsche Bank. $4.13 million worth of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) on Tuesday, August 8 with “Hold” rating. The stock of Mercadolibre Inc (NASDAQ:MELI) earned “Neutral” rating by JP Morgan on Tuesday, May 16. (NASDAQ:LGND) on Thursday, September 3 with “Buy” rating. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has “Buy” rating by TH Capital on Wednesday, September 30. More interesting news about Ligand Pharmaceuticals Inc. On Thursday, November 19 the stock rating was maintained by TH Capital with “Buy”. Roth Capital has “Buy” rating and $146 target. The firm earned “Buy” rating on Friday, December 18 by TH Capital. At present, 11 analysts recommended Holding these shares while 5 recommended sell, according to FactSet data.

11/21/2016 – Ligand Pharmaceuticals Incorporated had its “buy” rating reiterated by analysts at Roth Capital.

Analysts await PepsiCo, Inc. During the same quarter previous year, the company posted $0.50 earnings per share. The biotechnology company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.42. ValuEngine raised Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Therefore 38% are positive.

Analysts expect Galway Metals Inc (CVE:GWM) to report $-0.01 EPS on September, 4.After having $-0.03 EPS previously, Galway Metals Inc’s analysts see -66.67% EPS growth. Jefferies maintained PepsiCo, Inc. As per Wednesday, December 16, the company rating was initiated by Jefferies. The stock of PepsiCo, Inc. H.C. Wainwright has “Buy” rating and $160 target. The firm has “Buy” rating by Canaccord Genuity given on Thursday, June 1. The company was maintained on Friday, July 29 by Jefferies. The firm has “Buy” rating by Roth Capital given on Wednesday, September 30. UBS maintained PepsiCo, Inc. The firm has “Buy” rating given on Wednesday, July 26 by Mizuho. It also reduced Bill Barrett Corporation (NYSE:BBG) stake by 46,500 shares and now owns 18,000 shares. Ryman Hospitality Properties (NYSE:RHP) was raised too. TRUDELL CYNTHIA had sold 3,000 shares worth $337,775. Corporate insiders own 14.70% of the company’s stock. The company had a trading volume of 8,723 shares. Chadha Sanjeev sold $2.70M worth of PepsiCo, Inc.

Investors sentiment increased to 0.97 in 2016 Q4. It is positive, as 23 investors sold LGND shares while 85 reduced holdings. Citadel Advsrs Limited Co holds 0% or 2,066 shares in its portfolio. Neville Rodie & Shaw has 77,381 shares. Ami Asset holds 144,649 shares or 1.09% of its portfolio. (NYSE:PEP) for 96,340 shares. Profund Advisors Limited Liability Company holds 11,245 shares. 158.52 million shares or 2.18% less from 162.05 million shares in 2016Q3 were reported. Union Bank & Trust reported 1.4% stake. The Colorado-based Jbf Capital Inc. has invested 0.29% in the stock. Strs Ohio reported 0% stake. Flinton Capital Management LLC now owns 1,258 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 238 shares during the last quarter. Old Point Trust & N A stated it has 61,882 shares. (NASDAQ:LGND). Guggenheim Cap Limited Liability has 0.01% invested in Ligand Pharmaceuticals Inc.

Investors sentiment increased to 1.2 in Q4 2016. Its down 0.23, from 1.17 in 2016Q3. William Blair Investment Management LLC increased its position in Ligand Pharmaceuticals by 42.3% in the first quarter. 39 funds opened positions while 91 raised stakes. Moreover, Alps Advisors has 0.02% invested in Ligand Pharmaceuticals Inc. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 644 shares. (NASDAQ:LGND). Td Asset Management Inc owns 7,900 shares for 0% of their portfolio. 7,100 are held by Pacad Investment Ltd. Howe Rusling stated it has 0.03% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Blair William And Com Il owns 114,669 shares. The Maryland-based Proshare Lc has invested 0.02% in Ligand Pharmaceuticals Inc. Baker Bros Advsr LP holds 73,386 shares or 0.07% of its portfolio. The original version of this piece of content can be accessed at Van Eck Corp holds 252 shares. Finally, Eqis Capital Management Inc. raised its position in Ligand Pharmaceuticals by 0.6% in the second quarter.

Since February 13, 2017, it had 1 insider purchase, and 12 selling transactions for $117.28 million activity. The insider Donahoe John J bought 11,236 shares worth $1.10 million. $436,400 worth of Ligand Pharmaceuticals Inc.

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The corporation has a market cap of US$2.7 Billion. The Firm is involved in the development and licensing of biopharmaceutical assets. It has a 31.29 P/E ratio. The Firm employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. Another trade for 10.00M shares valued at $60.00 million was made by INCYTE CORP on Tuesday, February 14. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has declined 2.87% since August 11, 2016 and is downtrending. It has underperformed by 19.57% the S&P500.